Vascular BioSciences recently awarded a NIH SBIR/STTR Phase I Commercialization Assistance Award to develop the CAR peptide as a therapeutic adjuvant.

Oct 11, 2012
by admin
Comments are off

Vascular BioSciences recently awarded a NIH SBIR/STTR Phase I Commercialization Assistance Award to develop the CAR peptide as a therapeutic adjuvant.

Goleta, CA., October 11, 2012 – Vascular BioSciences recently awarded a NIH SBIR/STTR Phase I Commercialization Assistance Award to develop the CAR peptide as a therapeutic adjuvant.

CEO David Mann remarked, “The NIH SBIR/STTR Phase I Commercialization Assistance Award is a helpful step forward in commercializing our CAR peptide therapeutic adjuvant. We look forward to working with Foresight Science and Technology to develop a market entry strategy for our products.”

The National Health Institute (NIH) issues a Niche Assessment Program for those that wish to stimulate commercialization. In collaboration with the NIH SBIR/STTR awardees, the Foresight Science & Technology Incorporated provides a Technology Niche Analysis that presents a company with data about market-oriented information such as market size, potential consumers, and competing technologies. Companies selected to win the award are given an in-depth, unbiased assessment of appropriate market niches for products and given opportunities to connect with potential customers, licenses, investors, or commercial partners.

Next Steps: